|
1) McCormick JA, Bhalla V, Pao AC, et al. SGK1: a rapid aldosterone-induced regulator of renal sodium reabsorption. Physiology(Bethesda). 2005; 20: 134-9
|
|
|
|
|
2) Zhang W, Xia X, Reisenauer MR, et al. Aldo-sterone-induced Sgk1 relieves Dot1a-Af9-mediated transcriptional repression of epithelial Na＋ channel alpha. J Clin Invest. 2007; 117: 773-83
|
|
|
|
|
3) Wilson, FH, Disse-Nicodeme, S, Choate, KA, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001; 293: 1107-12
|
|
|
|
|
|
4) Xu B, English JM, Wilsbacher JL, et al. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J Biol Chem. 2000; 275: 16795-801
|
|
|
|
|
|
5) Kahle KT, Ring AM, Lifton RP. Molecular physi-ology of the WNK kinases. Annu Rev Physiol. 2008; 70: 329-55
|
|
|
|
|
|
6) Yang CL, Zhu X, Wang Z, et al. Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport. J Clin Invest. 2005; 115: 1379-87
|
|
|
|
|
|
7) Wade JB, Fang L, Liu J, et al. WNK1 kinase isoform switch regulates renal potassium excre-tion. Proc Natl Acad Sci U S A. 2006; 103: 8558-63
|
|
|
|
|
|
8) Ring AM, Leng Q, Rinehart J, et al. An SGK1 site in WNK4 regulates Na＋ channel and K＋ channel activity and has implications for aldosterone signaling and K＋ homeostasis. Proc Natl Acad Sci U S A. 2007; 104: 4025-9
|
|
|
|
|
|
9) Rozansky DJ, Cornwall T, Subramanya AR, et al. Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway. J Clin Invest. 2009; 119: 2601-12
|
|
|
|
|
|
10) Kahle KT, Wilson FH, Leng Q, et al. WNK4 regulates the balance between renal NaCl reab-sorption and K＋ secretion. Nat Genet. 2003; 35: 372-6
|
|
|
|
|
|
11) Blasi ER, Rocha R, Rudolph AE, et al. Aldo-sterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003; 63: 1791-800
|
|
|
|
|
|
12) Rodriguez-Iturbe B, Quiroz Y, Nava M, et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol. 2002; 282: F191-201
|
|
|
|
|
|
13) Leroy V, De Seigneux S, Agassiz V, et al. Aldosterone activates NF-kappaB in the collect-ing duct. J Am Soc Nephrol. 2009; 20: 131-44
|
|
|
|
|
|
14) Brown NJ. Salt in the wound. J Am Soc Nephrol. 2009; 20: 5-6
|
|
|
|
|
|
15) Wehling M, Neylon CB, Fullerton M, et al. Nongenomic effects of aldosterone on intra-cellular Ca2＋ in vascular smooth muscle cells. Circ Res. 1995; 76: 973-9
|
|
|
|
|
|
16) Haseroth K, Gerdes D, Berger S, et al. Rapid nongenomic effects of aldosterone in mineralo-corticoid-receptor-knockout mice. Biochem Biophys Res Commun. 1999; 266: 257-61
|
|
|
|
|
|
17) Grossmann C, Benesic A, Krug AW, et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005; 19: 1697-710
|
|
|
|
|
|
18) Mutoh A, Isshiki M, Fujita T. Aldosterone enhances ligand-stimulated nitric oxide pro-duction in endothelial cells. Hypertens Res. 2008; 31: 1811-20
|
|
|
|
|
19) Nishiyama A, Yao L, Fan Y, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005; 45: 710-6
|
|
|
|
|
|
20) Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003; 100: 14211-6
|
|
|
|
|
|
21) Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribu-tion of fat-derived factors. J Am Soc Nephrol. 2006; 17: 3438-46
|
|
|
|
|
|
22) Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003; 41: 64-8
|
|
|
|
|
|
23) Mizuno Y, Yoshimura M, Yasue H, et al. Aldo-sterone production is activated in failing ventricle in humans. Circulation. 2001; 103: 72-7
|
|
|
|
|
|
24) Young MJ, Clyne CD, Cole TJ, et al. Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab. 2001; 86: 5121-6
|
|
|
|
|
|
25) Lee SH, Yoo TH, Nam BY, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol. 2009; 297: F1381-90
|
|
|
|
|
|
26) Nishikawa T, Suematsu S, Saito J, et al. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol. 2005; 96: 309-16
|
|
|
|
|
|
27) Takeda Y, Yoneda T, Demura M, et al. Effects of high sodium intake on cardiovascular aldo-sterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens. 2001; 19: 635-9
|
|
|
|
|
|
28) Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270: 1491-4
|
|
|
|
|
|
29) Tronche F, Opherk C, Moriggl R, et al. Gluco-corticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev. 2004; 18: 492-7
|
|
|
|
|
|
30) Kawashima T, Bao YC, Nomura Y, et al. Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors. J Cell Biol. 2006; 175: 937-46
|
|
|
|
|
|
31) Wu X, Tu X, Joeng KS, et al. Rac1 activation controls nuclear localization of beta-catenin during canonical Wnt signaling. Cell. 2008; 133: 340-53
|
|
|
|
|
|
32) Shibata S, Nagase M, Yoshida S, et al. Modi-fication of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008; 14: 1370-6
|
|
|
|
|
|
33) Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hyper-tension exacerbated by pregnancy. Science. 2000; 289: 119-23
|
|
|
|
|
|
34) Yokota K, Shibata H, Kurihara I, et al. Coactivation of the N-terminal transactivation of mineralocorticoid receptor by Ubc9. J Biol Chem. 2007; 282: 1998-2010
|
|
|
|
|
|
35) Viengchareun S, Le Menuet D, Martinerie L, et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007; 5: e012
|
|
|
|
|
|
36) Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003; 93: 69-76
|
|
|
|
|
|
37) Rossier MF, Lenglet S, Vetterli L, et al. Cortico-steroids and redox potential modulate sponta-neous contractions in isolated rat ventricular cardiomyocytes. Hypertension. 2008; 52: 721-8
|
|
|
|
|
|
38) Massaad C, Houard N, Lombes M, et al. Modu-lation of human mineralocorticoid receptor function by protein kinase A. Mol Endocrinol. 1999; 13: 57-65
|
|
|
|
|
|
39) Oyamada N, Sone M, Miyashita K, et al. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology. 2008; 149: 3764-77
|
|
|
|
|
|
40) Tsugita M, Iwasaki Y, Nishiyama M, et al. Glucocorticoid receptor plays an indispensable role in mineralocorticoid receptor-dependent transcription in GR-deficient BE(2)C and T84 cells in vitro. Mol Cell Endocrinol. 2009; 302: 18-25
|
|
|
|
|
|
41) Fisher ND, Hurwitz S, Jeunemaitre X, et al. Adrenal response to angiotensin II in black hyper-tension: lack of sexual dimorphism. Hypertension. 2001; 38: 373-8
|
|
|
|
|